Vivoryon Therapeutics « Terug naar discussie overzicht

Vivoryon is de naam. Daarom nieuw draadje

6.265 Posts, Pagina: « 1 2 3 4 5 6 ... 309 310 311 312 313 314 | Laatste
Kaviaar
0
quote:

DeZwarteRidder schreef op 4 maart 2024 09:39:

[...]
Je zit er dus helemaal naast.
De dag van je leven gehad DZR. Je was weer “lekker” op dreef.
DeZwarteRidder
0
quote:

DeZwarteRidder schreef op 30 juli 2023 15:23:

[...]
Dat ziet er slecht voor Vivo en de patiënten:

From March 2015 to April 2017, the Phase 2 SAPHIR trial compared a 12-week course of twice-daily 800 mg PQ912 tablets to placebo. It enrolled 120 people with MCI or mild dementia due to AD as ascertained by CSF Aß levels at screening. This trial took place in seven European countries. It met its primary outcome of safety, with no difference in the frequency of adverse events between the treatment and placebo arms. The treatment group had more skin reactions and gastrointestinal problems than placebo, and more discontinuations. PQ912 inhibited QC activity in CSF by 92 percent. It appeared to slightly decrease pyroglutamate Aß oligomers in CSF, though CSF Aß oligomers' concentrations are near the assay’s detection limit. The treatment group showed a benefit on working memory and a trend on attention, but no difference on five other neuropsychological tests. On EEG readings, the treatment group showed a reversal of AD-induced changes in theta and alpha rhythms. In CSF, the synaptic marker neurogranin and the inflammatory marker YKL40 trended downward from a known rise in AD. CSF AD biomarkers were unchanged (Jun 2017 news; Scheltens et al., 2018; Briels et al., 2020).
Dit was dus al bekend in 2017.........!!!!!!
putdeksel
1
Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, and is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, self-neglect, and behavioral issues. As a person's condition declines, they tend to ignore red flags related to stock price movements and subsequently have to incur significant losses on their investments.
DeZwarteRidder
0
quote:

lucas D schreef op 20 november 2023 13:19:

Bij goedkeuring Alzheimer medicijn word
Vivoryon een > € 100,00 aandeel.
Ik weet niet wanneer jij aandelen hebt gekocht of verkocht, maar ik weet wel dat jij al ca 5 jaar valse reclame maakt voor Probiodrug/Vivoroyon.
lucas D
0
Vivoryon:

2023:
31 dec € 8,140 = ijkpunt einde maand winst/verlies

2024:

Slotkoers 31 januari € 8,820 = + 8,1 %
Slotkoers 29 februari € 8,500 = + 4,5%
Slotkoers 31 maart € 0,540 = - 93,2 %

Slotkoers vrijdag 01 maart € 8,400
Slotkoers vrijdag 08 maart € 0,521
Slotkoers vrijdag 15 maart € 0,559
Slotkoers vrijdag 22 maart € 0,545
Slotkoers vrijdag 29 maart € 0,540

De maand maart een slotkoers van € 0,540 dat is € 7,960 lager dan de voorgaande beursmaand.
Nieuws:
Blijft staan:

De slotkoers van maart is € 7,600 lager gesloten dan de slotkoers van 31 december 2023.

Hoogste dagkoers 15 februari € 9,800
Laagste dagkoers 15 maart € 0,500

Laatste maand lijst
6.265 Posts, Pagina: « 1 2 3 4 5 6 ... 309 310 311 312 313 314 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 18 jun 2024 17:35
Koers 1,974
Verschil 0,000 (0,00%)
Hoog 2,000
Laag 1,864
Volume 394.530
Volume gemiddeld 1.113.401
Volume gisteren 394.530

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront